Hints and tips:
Related Special Reports
Related Topics
US biotech has been struggling to overcome fall in demand for coronavirus jabs
Companies have yet to provide investors with convincing post-pandemic strategies
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
...Among the surprises: the company’s investments in bitcoin and ether and the inclusion of entities affiliated with OpenAI’s Sam Altman, Silicon Valley networker par excellence, among the biggest investors...
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
US drugmaker is trying to chart its future without blockbuster Covid-19 products
...The company may have missed out on the early flush of AI hype but it has also avoided rushing out a sub-par product that might harm its reputation....
...O’Neill thinks tokenised bonds have moved from trial phase to implementation and are on a par with conventional bond markets, in terms of liquidity and demand....
Millions of Paxlovid pills have gone unused as tight controls restrict access
...Both bonds were issued at a discount to par to attract investors. The bond’s guaranteed principal payment is expected to be AAA-rated by S&P, according to the World Bank....
...The stock is trading on 14 times forward earnings, on a par with Mattel. This seems overpriced given that Mattel has fared better sales-wise....
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
Doubts grow over safety and effectiveness of drugs that were marketed as coronavirus treatments
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...Total annual revenues for the US college football bowl division totalled $10bn in 2022, according to data from the Knight Commission on Intercollegiate Athletics, roughly on par with the annual revenues...
Investor worries about the impact of weight loss drugs on food companies are overdone
...The fast-food industry alone is worth about $180bn, on par with its market size in the US. This year, strong demand in China has boosted McDonald’s group earnings and same-store sales growth....
...Teresa Graham, chief of Roche’s pharmaceutical division, said more patients suffered from diseases of the immune system than from cancer, and the current drugs did not serve them well....
...The World Obesity Federation expects the economic cost of overweight and obesity to reach 3 per cent of global gross domestic product annually by 2035 — on par with the impact of Covid-19 in 2020....
Rare step comes after Brussels fined US biotech for buying Grail without approval
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
Biotech has been criticised for closing its $8bn acquisition of cancer test company Grail without regulatory approval
...The UK pharmaceutical retailer’s transfer of £4.8bn of pension obligations to insurer Legal & General brings its potential sale by owner Walgreens Boots Alliance one step closer....
International Edition